Literature DB >> 8564962

Mechanisms of interleukin-2-induced hepatic toxicity.

K Nakagawa1, F N Miller, D E Sims, A B Lentsch, M Miyazaki, M J Edwards.   

Abstract

Interleukin 2 (IL-2) mediates the regression of metastatic cancer, but its clinical use is limited by associated toxicities including hepatic dysfunction. To determine the mechanism for IL-2-induced hepatic dysfunction, we hypothesized that IL-2 activation of Kupffer cells causes leukocyte-endothelial adhesion and decreases hepatic sinusoidal blood flow. C57BL/6 mice were given injections of latex particles and prepared for intravital hepatic microscopy 2 h after i.p. IL-2 administration. Liver tissue was also prepared to quantitate hepatic tumor necrosis factor (TNF) mRNA and processed for light and electron microscopy. Phagocytosing Kupffer cells and leukocytes adherent to the endothelium were counted, and surface sinusoidal blood flow was quantitated. Kupffer cell activity was quantitated as the ratio of phagocytosing Kupffer cells to sinusoidal blood flow. IL-2 significantly increased Kupffer cell activity (0.56 +/- 0.05 for controls versus 0.84 +/- 0.05 for IL-2), significantly caused leukocyte-endothelial adhesion (26.7 +/- 7.9 for controls versus 87.0 +/- 27.6 for IL-2, WBC/mm2 endothelial surface), and significantly decreased the number of sinusoids containing blood flow per microscopic field (6.66 +/- 0.15 for controls versus 5.79 +/- 0.13 for IL-2) without causing changes in systemic hemodynamic parameters. In IL-2 treated livers, light and electron microscopy showed the constriction of sinusoids associated with swollen or ruptured mitochondria, which was consistent with hypoxic deterioration near central venules. Adherent platelets, neutrophils, and lymphocytes within sinusoids and central venules were also observed. PCR revealed that IL-2 significantly induced TNF mRNA expression in the liver. These data suggest that IL-2 activates Kupffer cells in association with the release of monokines including TNF, which causes activation of circulating leukocytes as well as hepatic sinusoidal endothelial cells. The resultant leukocyte and platelet adhesion to the endothelium may then physically impede the sinusoidal microcirculation, resulting in microscopic areas of hepatic ischemia and explaining the mechanism of IL-2-induced hepatic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8564962

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases.

Authors:  D Rowbotham; J Wendon; R Williams
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

2.  Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.

Authors:  Carsten Krieg; Sven Létourneau; Giuseppe Pantaleo; Onur Boyman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

3.  Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences.

Authors:  S Chaurasiya; P Hew; P Crosley; D Sharon; K Potts; K Agopsowicz; M Long; C Shi; M M Hitt
Journal:  Cancer Gene Ther       Date:  2016-05-06       Impact factor: 5.987

Review 4.  Epidemiology of acute liver failure.

Authors:  Mouen Khashab; A Joseph Tector; Paul Y Kwo
Journal:  Curr Gastroenterol Rep       Date:  2007-03

5.  The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy.

Authors:  M M Kemeny; G I Botchkina; M Ochani; M Bianchi; C Urmacher; K J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

6.  T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.

Authors:  Julien Laurent; Cedric Touvrey; Silke Gillessen; Magali Joffraud; Manuela Vicari; Caroline Bertrand; Stefano Ongarello; Bernd Liedert; Elisa Gallerani; Joachim Beck; Aurelius Omlin; Cristiana Sessa; Sonia Quaratino; Roger Stupp; Ulrike S Gnad-Vogt; Daniel E Speiser
Journal:  J Transl Med       Date:  2013-01-07       Impact factor: 5.531

7.  Chemotherapy induced liver abnormalities: an imaging perspective.

Authors:  Ankush Sharma; Roozbeh Houshyar; Priya Bhosale; Joon-Il Choi; Rajesh Gulati; Chandana Lall
Journal:  Clin Mol Hepatol       Date:  2014-09

8.  Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.

Authors:  Brendan Curti; Gregory A Daniels; David F McDermott; Joseph I Clark; Howard L Kaufman; Theodore F Logan; Jatinder Singh; Meenu Kaur; Theresa L Luna; Nancy Gregory; Michael A Morse; Michael K K Wong; Janice P Dutcher
Journal:  J Immunother Cancer       Date:  2017-12-19       Impact factor: 13.751

9.  Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation.

Authors:  Hua Jing; Michael Hettich; Simone Gaedicke; Elke Firat; Mark Bartholomä; Gabriele Niedermann
Journal:  J Immunother Cancer       Date:  2019-02-26       Impact factor: 13.751

10.  ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.

Authors:  Jared E Lopes; Jan L Fisher; Heather L Flick; Chunhua Wang; Lei Sun; Marc S Ernstoff; Juan C Alvarez; Heather C Losey
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.